Comparative Pharmacology
Head-to-head clinical analysis: OSELTAMIVIR versus TAMIFLU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSELTAMIVIR versus TAMIFLU.
Oseltamivir vs TAMIFLU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neuraminidase inhibitor; blocks influenza virus neuraminidase, preventing viral release and spread.
Oseltamivir phosphate is a prodrug that is hydrolyzed to the active metabolite oseltamivir carboxylate, a selective inhibitor of influenza virus neuraminidase, an enzyme required for viral replication and release from infected cells.
75 mg orally twice daily for 5 days for treatment; 75 mg orally once daily for prophylaxis for at least 10 days.
75 mg orally twice daily for 5 days
None Documented
None Documented
Oseltamivir carboxylate terminal half-life: 6-10 hours (mean 7.7 hours) in healthy adults; prolonged in renal impairment (up to 20 hours in creatinine clearance <30 mL/min, requiring dose adjustment).
Clinical Note
moderateProbenecid + Oseltamivir
"The serum concentration of the active metabolites of Oseltamivir can be increased when Oseltamivir is used in combination with Probenecid."
Terminal elimination half-life of oseltamivir carboxylate is 4.4 hours (range 3.9–5.0 h) in healthy adults, allowing twice-daily dosing; prolonged to 18–24 hours in severe renal impairment (CrCl <10 mL/min).
Renal excretion: >90% of absorbed oseltamivir is eliminated as oseltamivir carboxylate (active metabolite) via glomerular filtration and tubular secretion; biliary/fecal: <20% as oseltamivir carboxylate; approximately 75% of an oral dose appears in urine as oseltamivir carboxylate; unchanged oseltamivir <5% in urine.
Renal excretion of the active metabolite oseltamivir carboxylate accounts for >90% of absorbed drug via glomerular filtration and tubular secretion; <1% excreted as parent oseltamivir in urine; fecal elimination <5%.
Category A/B
Category C
Neuraminidase Inhibitor
Neuraminidase Inhibitor